This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bondzi, C. Articles by Krystal, G. W. Search for Related Content PubMed PubMed Citation Articles by Bondzi, C. Articles by Krystal, G. W.

Src Family Kinase Activity Is Required for Kit-mediated Mitogen-activated Protein (MAP) Kinase Activation, However Loss of Functional Retinoblastoma Protein Makes MAP Kinase Activation Unnecessary for Growth of Small Cell Lung Cancer Cells¹

Departments of Microbiology/Immunology [C. B., G. W. K.], Medicine [J. L., G. W. K.], and Radiation Oncology [P. D.], Medical College of Virginia of Virginia Commonwealth University and McGuire Veterans Affairs Medical Center, Richmond, Virginia 23249

Small cell lung cancer (SCLC) is characterized by multiple genetic alterations that include inactivation of the retinoblastoma protein (Rb), the establishment of several autocrine loops including that induced by coexpression of stem cell factor (SCF) and Kit, and the ectopic expression and activation of Src family kinases. Previous studies have shown that Lck associates with, and becomes activated by, Kit after SCF stimulation of SCLC cells. In the present study, we have demonstrated that PP1, a pharmacological inhibitor of Src kinases, blocked SCF-mediated activation of mitogen-activated protein (MAP) kinase, but it also inhibited Kit activation. However, MAP kinase activation was more sensitive than Kit activation to the effects of PP1. Overexpression of Lck reduced the sensitivity of MAP kinase activation to PP1 without altering the sensitivity of Kit activation, which suggested a role for Lck in SCF-mediated MAP kinase activation. Inducible expression of a dominant negative Lck inhibited MAP kinase activation in a dose-dependent manner, which confirmed that Src family kinase activity is required for SCF-induced MAP kinase activation. The growth of cells that expressed dominant negative Lck was unaffected, however, despite the inhibition of MAP kinase. Growth was also unaffected by the inhibition of the MAP kinase pathway using PD 98059, but sensitivity to the MAP/extracellular signal-regulated kinase kinase inhibitor could be partially restored by expression of wild-type Rb. Therefore, MAP kinase activation seems to be dispensable for the growth of SCLC only in the absence of Rb expression. These data suggest that the SCF/Kit autocrine loop, through activation of Lck and subsequently MAP kinase, and the mutational inactivation of Rb contribute to the loss of G₁-S phase checkpoint regulation during the pathogenesis of SCLC. Furthermore, the data demonstrate that, in established SCLC cell lines, proliferative signal transduction initiated by Kit is mediated by pathways other than the classic MAP kinase pathway.

This article has been cited by other articles:

				M. Danbara, M. Yoshida, Y. Kanoh, S.-X. Jiang, N. Masuda, T. Akahoshi, and M. Higashihara Flow Cytometric Detection of Small Cell Lung Cancer Cells with Aberrant CD45 Expression in Micrometastatic Bone Marrow Jpn. J. Clin. Oncol., November 1, 2009; 39(11): 771 - 775. [Abstract] [Full Text] [PDF]

				B. Li, J. Berman, J.-T. Tang, and T.-J. Lin The Early Growth Response Factor-1 Is Involved in Stem Cell Factor (SCF)-induced Interleukin 13 Production by Mast Cells, but Is Dispensable for SCF-dependent Mast Cell Growth J. Biol. Chem., August 3, 2007; 282(31): 22573 - 22581. [Abstract] [Full Text] [PDF]

				G. Rossi, A. Cavazza, A. Marchioni, L. Longo, M. Migaldi, G. Sartori, N. Bigiani, L. Schirosi, C. Casali, U. Morandi, et al. Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFR{alpha}, PDGFR{beta}, and Met in Large-Cell Neuroendocrine Carcinoma of the Lung J. Clin. Oncol., December 1, 2005; 23(34): 8774 - 8785. [Abstract] [Full Text] [PDF]

				C.-M. Tsang, C.-K. Wong, W.-K. Ip, and C. W.-K. Lam Synergistic effect of SCF and TNF-{alpha} on the up-regulation of cell-surface expression of ICAM-1 on human leukemic mast cell line (HMC)-1 cells J. Leukoc. Biol., July 1, 2005; 78(1): 239 - 247. [Abstract] [Full Text] [PDF]

				E. Tamborini, L. Bonadiman, T. Negri, A. Greco, S. Staurengo, P. Bidoli, U. Pastorino, M. A. Pierotti, and S. Pilotti Detection of Overexpressed and Phosphorylated Wild-Type Kit Receptor in Surgical Specimens of Small Cell Lung Cancer Clin. Cancer Res., December 15, 2004; 10(24): 8214 - 8219. [Abstract] [Full Text] [PDF]

				C. M. Rohde, J. Schrum, and A. W.-M. Lee A Juxtamembrane Tyrosine in the Colony Stimulating Factor-1 Receptor Regulates Ligand-induced Src Association, Receptor Kinase Function, and Down-regulation J. Biol. Chem., October 15, 2004; 279(42): 43448 - 43461. [Abstract] [Full Text] [PDF]

				F. H. Blackhall, M. Pintilie, M. Michael, N. Leighl, R. Feld, M.-S. Tsao, and F. A. Shepherd Expression and Prognostic Significance of Kit, Protein Kinase B, and Mitogen-activated Protein Kinase in Patients with Small Cell Lung Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2241 - 2247. [Abstract] [Full Text] [PDF]

				O. Voytyuk, J. Lennartsson, A. Mogi, G. Caruana, S. Courtneidge, L. K. Ashman, and L. Ronnstrand Src Family Kinases Are Involved in the Differential Signaling from Two Splice Forms of c-Kit J. Biol. Chem., March 7, 2003; 278(11): 9159 - 9166. [Abstract] [Full Text] [PDF]

				L. Tatton, G. M. Morley, R. Chopra, and A. Khwaja The Src-selective Kinase Inhibitor PP1 Also Inhibits Kit and Bcr-Abl Tyrosine Kinases J. Biol. Chem., February 7, 2003; 278(7): 4847 - 4853. [Abstract] [Full Text] [PDF]

				G. W. Krystal, G. Sulanke, and J. Litz Inhibition of Phosphatidylinositol 3-Kinase-Akt Signaling Blocks Growth, Promotes Apoptosis, and Enhances Sensitivity of Small Cell Lung Cancer Cells to Chemotherapy Mol. Cancer Ther., September 1, 2002; 1(11): 913 - 922. [Abstract] [Full Text] [PDF]